Cutaneous leishmaniasis: Disease susceptibility and pharmacogenetic implications

Pharmacogenomics

Volumn 10, Issue 3, 2009, Pages 451-461

  Ameen, Mahreen ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Cutaneous; Genetic; Leishmania; Leishmaniasis; Mucocutaneous; Susceptibility; Therapy; Visceral

Indexed keywords

AMPHOTERICIN B; CYTOCHROME P450 3A5; GAMMA INTERFERON; HLA ANTIGEN CLASS 2; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR BETA; INTERLEUKIN 4 ANTIBODY; INTERLEUKIN 6; LYMPHOTOXIN; MEGLUMINE ANTIMONATE; MILTEFOSINE; MULTIDRUG RESISTANCE PROTEIN 1; NATURAL RESISTANCE ASSOCIATED MACROPHAGE PROTEIN 1; PAROMOMYCIN; PENTAMIDINE; PYRROLE DERIVATIVE; STIBOGLUCONATE SODIUM; TUMOR NECROSIS FACTOR ALPHA; PROTOZOAL VACCINE;

CLINICAL FEATURE; CRYOTHERAPY; DISEASE COURSE; DISEASE PREDISPOSITION; ETHNIC DIFFERENCE; GENE IDENTIFICATION; GENE MAPPING; GENETIC ASSOCIATION; GENOTYPE; HLA TYPING; HOST PARASITE INTERACTION; HUMAN; HYPERTHERMIC THERAPY; LEISHMANIA BRAZILIENSIS; LEISHMANIA DONOVANI; LEISHMANIA MAJOR; LEISHMANIA MEXICANA; LEISHMANIA PANAMENSIS; LEISHMANIA TROPICA; NONHUMAN; PARASITE IDENTIFICATION; PATHOGENESIS; PHARMACOGENETICS; PROGNOSIS; REVIEW; SKIN LEISHMANIASIS; TREATMENT RESPONSE; ANIMAL; CHROMOSOME MAP; ENVIRONMENT; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENETICS; IMMUNOLOGY; LEISHMANIA; METHODOLOGY; PATHOGENICITY;

PROTOZOA;

ANIMALS; CHROMOSOME MAPPING; DISEASE SUSCEPTIBILITY; ENVIRONMENT; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HUMANS; LEISHMANIA; LEISHMANIASIS, CUTANEOUS; PHARMACOGENETICS; PROTOZOAN VACCINES;

EID: 65649145422     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.10.3.451     Document Type: Review

References (113)

1. Desjeux P: Leishmaniasis: current situation and new perspectives. Comp. Immunol. Microbiol. Infect. Dis. 27, 305-318 (2004).
2. Desjeux P: The increase in risk factors for leishmaniasis worldwide. Trans. R. Soc. Trop. Med. Hyg. 95(3), 239-243 (2001).
3. Reyburn H, Rowland M, Mohsen M, Khan B, Davies C: The prolonged epidemic of anthroponotic cutaneous leishmaniasis in Kabul, Afghanistan: 'bringing down the neighbourhood'. Trans. R. Soc. Trop. Med. Hyg. 97(2), 170-176 (2003).
4. Lawn SD, Whetham J, Chiodini PL et al.: New world mucosal and cutaneous eishmaniasis: an emerging health problem among British travellers. QJM 97(12), 781-788 (2004).
5. Weina PJ, Neafie RC, Wortmann G et al.: Old world leishmaniasis: an emerging infection among deployed US military and civilian workers. Clin. Infect. Dis. 39 (11), 1674-1680 (2004).
6. Maroli M, Rossi L, Baldelli R et al.: The northward spread of leishmaniasis in Italy: evidence from retrospective and ongoing studies on the canine reservoir and phlebotomine vectors. Trop. Med. Int. Health 13(2), 256-264 (2008).
7. Dujardin JC, Campino L, Cañavate C et al.: Spread of vector-borne diseases and neglect of leishmaniasis, Europe. Emerging Infect. Dis. 14(7), 1013-1018 (2008).
8. Karunaweera ND, Prationg F, Siriwardane HV, Ihalamulla RL, Dedet JP: Leishmania donovani MON-37 is the causative agent of cutaneous leishmaniasis in Sri Lanka. Trans. R. Soc. Trop. Med. Hyg. 97, 380-381 (2003).
9. Sharma NL, Mahajan VK, Kanga A et al.: Localized cutaneous leishmaniasis due to Leishmania donovani and Leishmania tropica: preliminary findings of the study of 161 new cases from a new endemic focus in Himachal Pradesh, India. Am. J. Trop. Med. Hyg. 72, 819-824 (2005).
10. Herwaldt BL: Leishmaniasis. Lancet 354, 1191-1199 (1999).
11. Reed SG, Scott P: T-cell and cytokine responses in leishmaniasis. Curr. Opin. Immunol. 5, 524-531 (1993).
12. Sacks D, Noben-Trauth N: The immunology of susceptibility and resistance to Leishmania major in mice. Nat. Rev. Immunol. 2(11), 845-858 (2002).
13. Alexander J, Bryson K: T helper (h)1/Th2 and Leishmania: paradox rather than paradigm. ImmunoL Lett. 99 (1), 17-23 (2005).
14. Mansueto P, Vitale G, Di Lorenzo C, Rini GB, Mansucto S, Cillari E: Immunopathology of leishmaniasis: an update. Int. J. Immunopathol. Pharmacol. 20(3), 435-445 (2007).
15. Melby PC, Andrade-Narvaez FJ, Darnell BJ, Valencia-Pacheco G, Tryon VV, Palomo-Cetina A: Increased expression of proinflammatory cytokines in chronic lesions of human cutaneous leishmaniasis. Infect. Immun. 62(3), 837-842 (1994).
16. Pirmez C, Yamamura M, Uyemura K, Paes-Oliveira M, Concei-cecão-Silva F, Modlin RL: Cytokine patterns in the pathogenesis of human leishmaniasis. J. Clin. Invest. 91(4), 1390-1395 (1993).
17. Machado-Coelho GL, Caiaffa WT, Genaro O, Magathäes PA, Mayrink W: Risk factors for mucosal manifestation of American cutaneous leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 99 (1), 55-61 (2005).
18. Pasqua F, Ena J, Sanchez R et al.: Leishmaniasis as an opportunistic infection in HIV-infected patients: determinants of relapse and mortality in a collaborative study of 228 episodes in a Mediterranean region. Eur. J. Clin. Microbiol. Infect. Dis. 24(6), 411-418 (2005).
19. Gillespie RD, Mbow ML, Titus RG: The immunomodulatory factors of bloodfeeding arthropod saliva. Parasite Immunol. 98, 153-159 (2000).
20. Reithinger R, Dujardin JC, Louzir H, Pirmez C, Alexander B, Brooker S: Cutaneous leishmaniasis. Lancet Infect. Dis. 7(9), 581-596 (2007).
21. Lukes J, Mauricio IL, Schönian G et al,: Evolutionary and geographical history of the Leishmania donovani complex with a revision of current taxonomy. Proc. Natl. Acad. Sci. USA 104(22), 9375-9380 (2007).
22. Buxbaum LU, Denise H, Coombs GH, Alexander J, Mottfam JC, Scott P: Cysteine protease B of Leishmania mexicana inhibits host Th1 responses and protective immunity. J. Immunol. 171, 3711-3717 (2003).
23. Kelly BL, Stetson DB, Locksley RM: Leishmania major LACK antigen is required for efficient vertebrate parasitization. J. Exp. Med. 198, 1689-1698 (2003).
24. Cupolillo E, Brahim LR, Toaldo CB et al.: Genetic polymorphism and molecular epidemiology of Leishmania (Viannia) braziliensis from different hosts and geographic areas in Brazil. J. Clin. Microbiol. 41(7), 3126-3132 (2003).
25. Schriefef A, Schriefer AL, Góes-Neto A et al.: Multiclonal Leishmania braziliensis population structure and its clinical implication in a region of endemicity for American tegumentary leishmaniasis. Infect. Immun. 72(1), 508-514 (2004).
26. Zerpa O, Ulrich M, Blanco B et al.: Diffuse cutaneous leishmaniasis responds to mittefosine but then relapses. Br. J Dermatol. 156(6), 1328-1335 (2007).
27. Marovich MA, Lira R, Shepard M et al.: Leishmaniasis recidivans recurrence after 43 years: a clinical and immunologic report after successful treatment. Clin. Infect. Dis. 33(7), 1076-1079 (2001).
28. Ganguly S, Das NK, Panja M et al.: Increased levels of interleukin-10 and IgG3 are hallmarks of Indian post-kala-azar dermal leishmaniasis. J. Infect. Dis. 197(12), 1762-1771 (2008).
29. Zijlstra EE, Musa AM, Khalil EA, el-Hassan IM, el-Hassan AM: Post-kala-azar dermal leishmaniasis. Lancet Infect. Dis. 3 (2), 87-98 (2003).
30. Marsden PD: Mucosal leishmaniasis ('espundia'). Trans. R. Soc. Trop. Med. Hyg. 80, 859-876 (1986).
31. Collin S, Davidson R, Ritmeijer K et al.: Conflict and kala-azar: determinants of adverse outcomes of kala-azar among patients in southern Sudan. Clin. Infect. Dis. 38(5), 612-619 (2004).
32. Alvar J, Canavate C, Gutierrez-Solar B et al.: Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin. Microbiol. Rev. 10, 298-319 (1997).
33. Wortmann G, Hochberg L, Houng HH et al.: Rapid identification of Leishmania complexes by a real-time PCR assay. Am. J. Trop. Med. Hyg. 73 (6), 999-1004 (2005).
34. Murray HW, Berman JD, Davies CR, Saravia NG: Advances in leishmaniasis. Lancet 366, 1561-1577 (2005).
35. David C, Dimier-David L, Vargas F, Torrez M, Dedet J P: Fifteen years of cutaneous and mucocutaneous leishmaniasis in Bolivia: a retrospective study. Trans. R. Soc. Trop. Med. 73, 339-345 (1993).
36. Olliaro PL, Guerin PJ, Gefstl S, Haaskjold AA, Rottingen JA, Sundar S: Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004. Lancet Infect. Dis. 5(12), 763-774 (2005).
37. Ameen M: Cutaneous leishmaniasis: therapeutic strategies and future directions. Expert Opin. Pharmacother. 8(16), 2689-2699 (2007).
38. Amato VS, Tuon FF, Bacha HA, Neto VA, Nicodemo AC: Mucosal leishmaniasis. Current scenario and prospects for treatment. Acta Trop. 105(1), -9 (2008).
39. Blum J, Desjeux P, Schwartz E, Beck B, Harz C: Treatment of cutaneous leishmaniasis among travellers. J. Antimicrob. Chemother. 53(2), 158-166 (2004).
40. Bailey MS, Green AD, Ellis CJ et al.: Clinical guidelines for the management of cutaneous leishmaniasis in British military personnel. J. R. Army Med. Corps. 151(2), 73-80 (2005).
41. Modabber F: Experiences with vaccines against cutaneous leishmaniasis: of mice and men. Parasitology 98(Suppi.), S49-S60 (1989).
42. Requena JM, Iborra S, Carrion J, Alonso C, Soto M: Recent advances in vaccines for leishmaniasis. Expert Opin. Biol. Ther. 4, 1505-1517 (2004).
43. Ivens AC, Peacock CS, Worthey EA et al.: The genome of the kinetoplastid parasite Leishmania major. Science 309, 136-442 (2005).
44. Stober CB, Lange UG, Roberts MT et al.: From genome to vaccines for leishmaniasis: screening 100 novel vaccine candidates against murine Leishmania major infection. Vaccine 24(14), 2602-2616 (2006).
45. Convit J, Ulrich M, Zerpa O et al.: Immunotherapy of American cutaneous leishmaniasis in Venezuela during the period 1990-1999. Trans. R. Soc. Trop. Med. Hyg. 97(4), 469-472 (2003).
46. Convit J, Ulrich M, Polegre MA et al.: Therapy of Venezuelan patients with severe mucocutaneous or early lesions of diffuse cutaneous leishmaniasis with a vaccine containing pasteurized Leishmania promastigotes and Bacillus Calmette-Guerrin - preliminary report. Mem. Inst. Oswaldo Cruz 91(l), 57-62 (2004).
47. Musa AM, Khalil EA, Mahgoub FA et al.: Leishmaniasis Research Group/Sudan. Immunochemotherapy of persistent post-kala-azar dermal leishmaniasis: a novel approach to treatment. Trans. R. Soc. Trop. Med. Hyg. 102(1), 58-63 (2008).
48. Jones TC, Johnson WD, Barreto AC et al.: Epidemiology of American leishmaniasis due to Leishmania braziliensis braziliensis. J. Infect. Dis. 156, 73-83 (1987).
49. Castellucci L, Cheng LH, Araújo C et al.: Familial aggregation of mucosal leishmaniasis in northeast Brazil. Am. J Trop. Med. Hyg. 73(1), 69-73 (2005).
50. Walton BC, Valverde L: Racial differences in espundia. Ann. Trop. Med. Parasitol. 73 (1), 23-29 (1979).
51. Al-Gindan Y, Abdul-Aziz O, Kubba R: Cutaneous leishmaniasis in Al-Hassa, Saudi Arabia. Int. J. Dermatol. 23 (3), 194-197 (1984).
52. Shaw MA, Davies CR, Llanos-Cuentas EA, Collins A: Human genetic susceptibility and infection with Leishmania peruviana. Am. J. Hum. Genet. 57(5), 1159-1168 (095).
53. Alcaïs A, Abel L, David C, Torrez ME, Flandre P, Dedet JP: Evidence for a major gene controlling susceptibility to tegumentary leishmaniasis in a recently exposed Bolivian population. Am. J. Hum. Genet. 61(4), 968-979 (1997).
54. Samaranayake TN, Dissanayake VH, Fernando SD: Clinical manifestations of cutaneous leishmaniasis in Sri Lanka - possible evidence for genetic susceptibility among the Sinhalese. Ann. Trop. Med. Parasitol. 102(5), 383-390 (2008).
55. Mebrahtu YB, van Eys G, Guizani I et al.: Human cutaneous leishmaniasis caused by Leishmania donovani s.l. in Kenya. Trans. R. Soc. Trop. Med. Hyg. 87(5), 598-601 (1993).
56. Pratlong F, Bastien P, Perello R, Lami P, Dedet JP: Human cutaneous leishmaniasis caused by Leishmania donovani sensu stricto in Yemen. Trans. R. Soc. Trop. Med. Hyg. 89, 398-399 (1995).
57. Antoniou M, Haralambous C, Mazeris A et al.: Leishmania donovani leishmaniasis in Cyprus. Lancet Infect. Dis. 8 (1), 6-7 (2008).
58. Cabello PH, Lima AM, Azevedo ES, Kriger H: Familial aggregation of Leishmania chagasi infection in northeastern Brazil. Am. J. Trop. Med. Hyg. 52, 364-365 (1995).
59. Peacock CS, Collins A, Shaw MA et al.: Genetic epidemiology of visceral leishmaniasis in northeastern Brazil. Genet. Epidemiol. 20, 383-396 (2001).
60. Zijlstra EE, El Hassan AM, Ismael A, Ghalib HW: Endemic kala-azar in Eastern Sudan, a longitudinal study on the incidence of clinical and subclinical infection and post-kala-azar dermal leishmaniasis. Am. J. Trop. Med. Hyg. 51, 826-836 (1994).
61. Ibrahim ME, Lambson B, Yousif AO et al.: Kala-azar in a high transmission focus: An ethnic and geographic dimension. Am. J. Trop. Med. Hyg. 61, 941-944 (1999).
62. Handman E, Elso C, Foote S: Genes and susceptibility to leishmaniasis. Adv. Parasitol. 59, 1-75 (2005).
63. Blackwell J, Freeman J, Bradley D: Influence of H-2 complex on acquired resistance to Leishmania donovani infection in mice. Nature 283(5742), 72-74 (1980).
64. Vidal S, Tremblay ML, Govoni G et al.: The Ity/Lsh/Bcg locus: natural resistance to infection with intracellular parasites is abrogated by disruption of the Nramp1 gene. J. Exp. Med. 182(3), 655-666 (1995).
65. Roberts LJ, Baldwin TM, Curtis JM, Handman E, Foote SJ: Resistance to Leishmania major is linked to the H2 region on chromosome 17 and to chromosome 9. J. Exp. Med. 185 (9), 1705-1710 (1997).
66. Lipoldová M, Svobodová M, Krulová M et al.: Susceptibility to Leishmania major infection in mice: multiple loci and heterogeneity of immunopathological phenotypes. Genes Immun. 1(3), 200-206 (2000).
67. Heinzei FP, Sadick MD, Holaday BJ, Coffman RL, Locksley RM: Reciprocal expression of interferon-γ or interleukin 4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets. J. Exp. Med. 169(1), 59-72 (1989).
68. Foote SJ, Handman E: Genetics of murine leishmaniasis. Brief Funct. Genomic. Proteomic. 4(3), 270-276 (2005).
69. Lipoldová M, Demant P: Genetic susceptibility to infectious disease: lessons from mouse models of leishmaniasis. Nat. Rev. Genet. 7(4), 294-305 (2006).
70. Lara ML, Layrisse Z, Scorza JV et al.: Immunogenetics of human American cutaneous leishmaniasis. Study of HLA haplotypes in 24 families from Venezuela. Hum. Immunol. 30(2), 129-135 (1991).
71. Petzl-Erler ML, Belich MP, Queiroz-Telles F: Association of mucosal leishmaniasis with HLA. Hum. Immunol. 32(4), 254-260 (1991).
72. Barbier D, Demenais F, Lefait JF et al.: bility to human cutaneous leishmaniasis and HLA, Gin, Kin markers. Tissue Antigens 30(2), 63-67 (1987).
73. Olivo-Diaz A, Debaz H, Alaez C et al.: Role of HLA class II alleles in susceptibility to and protection from localized cutaneous leishmaniasis. Hum. Immunol. 65(3), 255-261 (2004).
74. Singh N, Sundar S, Williams F et al.: Molecular typing of HLA class I and class II antigens in Indian kala-azar patients. Trop. Med. Int. Health 2(5), 468-471 (1997).
75. Peacock CS, Sanjeevi CB, Shaw MA et al.: Genetic analysis of multicase families of visceral leishmaniasis in northeastern Brazil: no major role for class II or class III regions of HLA. Genes Immun. 3(6), 350-358 (2002).
76. Castes M, Trujillo D, Rojas ME et al.: Serum evels of turnour necrosis factor in patients with American cutaneous lesihmaniasis. Biol. Res. 26, 233-238 (1993).
77. Barral-Netto M, Badaró R, Barral A et al.: Tumor necrosis factor (cachectin) in human visceral leishmaniasis. J. Infect. Dis. 163 (4), 853-857 (1991).
78. Cabrera M, Shaw MA, Shraples C et al.: Polymorphism in tumour necrosis factor genes associated with mucocutaneous leishmaniasis. J. Exp. Med. 182 (5), 1259-1264 (1995).
79. Karplus TM, Jeronimo SM, Chang H et al.: Association between the tumor necrosis factor locus and the clinical outcome of Leishmania chagasi infection. Infect. Immun. 70 (12), 6919-6925 (2002).
80. Meddeb-Garnaoui A, Gritli S, Garbouj S et al.: Association analysis of HLA-class II and class III gene polymorphisms in the susceptibility to mediterranean visceral leishmaniasis. Hum. Immunol. 620), 509-517 (2001).
81. Kamali-Sarvestani E, Rasouli M, Mortazavi H, Gharesi-Fard B: Cytokine gene polymorphisms and susceptibility to cutaneous leishmaniasis in Iranian patients. Cytokine 35 (3-4), 159-165 (2006).
82. Chatelain R, Varkila K, Coffman RL: IL-4 induces a Th2 response in Leishmania major-infected mice. J. Immunol. 148 (4), 1182-1187 (1992).
83. Kopf M, Brombacher F, Köhler G et al.: IL-4-deficient Balb/c mice resist infection with Leishmania major. J. Exp, Med. 184 (3), 127-1136 (1996).
84. +) T cell depletion and T helper cell Type 1-selective cytokine therapy. J. Exp. Med. 189 (12), 1895-1906 (1999).
85. Mohamed HS, Ibrahim ME, Miller EN et al.: Genetic susceptibility to visceral leishmaniasis in The Sudan: linkage and association with IL4 and IFNGR1 Genes Immun. 4, 351-355 (2003).
86. Salhi A, Rodrigues V Jr, Santoro F et al.: Immunological and genetic evidence for a crucial role of IL-10 in cutaneous lesions in humans infected with Leishmania braziliensis. J Immunol. 180(9), 6139-6148 (2008).
87. Bacellar O, Lessa H, Schriefer A et al.: Up-regul2tion of Th1-type responses in mucosal leishmaniasis patients. Infect. Immun. 70, 6734-6740 (2002).
88. Hatzigeorgiou DE, He S, Sobel J, Grabstrin KH, Hafner A, Ho JL: IL-6 down-modulates the cytokine-enhanced antileishmanial activity in human macrophages. J. Immunol. 151, 3682-3692 (1993).
89. Castellucci L, Menezes E, Oliveira J et al.: IL6 -174 G/C promoter polymorphism influences susceptibility to mucosal but not localized cutaneous leishmaniasis in Brazil. J. Infect. Dis. 194(4), 519-527 (2006).
90. Bucheton B, Abel L, El-Safi S et al.: A major susceptibility locus on chromosome 22q12 plays a critical role in the control of kala-azar. Am. J. Hum. Genet. 73, 1052-1060 (2003).
91. Barral-Netto M, Barral A, Santos SB et al.: Soluble IL-2 receptor as an agent of serum-mediated suppression in human visceral leishmaniasis. J. Immunol. 147(1), 281-284 (1991).
92. Bucheton B, Argiro, L, Chevillard C et al.: Identification of a novel G245R polymorphism in the IL-2 receptor-β membrane proximal domain associated with human visceral leishmaniasis. Genes Immun. 8(1), 79-83 (2007).
93. Miller EN, Fadl M, Mohamed HS et al.: Y chromosome lineage- and village-specific genes on chromosomes 1p22 and 6q27 control visceral leishmaniasis in Sudan. PLoS Genet. 3(5), E71 (2007).
94. Jamieson SE, Miller EN, Peacock CS et al.: Genome-wide scan for visceral leishmaniasis susceptibility genes in Brazil. Genes Immun. 8(1), 84-90 (2007).
95. Jamieson SE, Miller EN, Black GF et al.: Evidence for a cluster of genes on chromosome 17q11-q21 controlling susceptibility to tuberculosis and leprosy in Brazilians. Genes Immun. 5(1), 46-57 (2004).
96. Jeronimo SM, Holst AK, Jamieson SE et al.: Genes at human chromosome 5q31.1 regulate delayed-type hypersensitivity responses associated with Leishmania chagasi infection. Genes Immun. 8(7), 539-551 (2007).
97. Jeronimo SM, Duggal P, Ettinger NA et al.: Genetic predisposition to self-curing infection with the protozoan Leishmania chagasi: a genomewide scan. J. Infect. Dis. 196, 1261-1269 (2007).
98. Bellamy R, Ruwende C, Corrah T, McAdam KPWJ, Whittle HC, Hill AVS: Variation in the NRAMP1 gene is associated with susceptibility to tuberculosis in West Africans. N. Engl. J. Med. 338, 640-644 (1998).
99. Bucheton B, Abel L, Kheir MM et al.: Genetic control ofvisceral leishmaniasis in a Sudanese population: candidate gene testing indicates a linkage to the NRAMP1 region. Genes Immun. 4, 104-109 (2003).
100. Mohamed HS, Ibrahim ME, Miller EN et al.: SLC11A1 (formerly NRAMP1) and susceptibility to visceral leishmaniasis in the Sudan. Eur. J. Hum. Genet. 12, 66-74 (2004).
101. Blackwell JM: SLC11A1 (formerly NRAMP1) and disease resistance. Cell. Microbiol. 3, 773-784 (2001).
102. Alonso DP, Ferreira AF, Ribolla PE et al.: Genotypes ofthe mannan-binding lectin gene and susceptibility to visceral leishmaniasis and clinical complications. J. Infect. Dis. 195, 1212-1217 (2007).
103. Salih MA, Ibrahim ME, Blackwell JM et al.: IFNG and IFNGR1 gene polymorphisms and susceptibility to post-kala-azar dermal leishmaniasis in Sudan. Genes Immun. 8(1), 75-78 (2007).
104. Casanova JL, Abel L: Genetic dissection of immunity to mycobacteria: The Human Model. Annu. Rev. Immunol, 20, 581-620 (2002).
105. Kane MM, Mosser DM: The role of IL-10 in promoting disease progression in lesihmaniasis. J. Immunol. 166, 1141-1147 (2001).
106. Bourreau E, Prevot G, Gardon J, Pradinaud R, Launois P: High intralesional interleukin-10 messenger RNA expression in localized cutaneous leishmaniasis is associated with unresponsiveness to treatment. J. Infect. Dis. 184 ,1628-1630 (2001).
107. Nylén S, Sacks D: Interleukin-10 and the pathogenesis of human visceral leishmaniasis. Trends Immunol. 28 (9), 378-384 (2007).
108. Saha S, Mondal S, Ravindran R et al.: IL-10- and TGF-β-mediated susceptibility in kala-azar and post-kala-azar dermal leishmaniasis: the significance of amphotericin B in the control of Leishmania donovani infection in India. J. Immunol. 179(8), 5592-5603 (2007).
109. Melby PC, Andrade-Narvaez F, Darnell BJ, Valencia-Pacheco G: In situ expression of interleukin-10 and interleukin-12 in active human cutaneous leishmaniasis. FEMS Immunol. Med. Microbiol. 15, 101-107 (1996).
110. Louzir H, Melby PC, Ben Salah A et al.: Immunologic determinants of disease evolution in localized cutaneous leishmaniasis due to Leishmania major. J. Infect. Dis. 177, 1687-1695 (1998).
111. Faria DR, Gollob KJ, Barbosa J Jr et al.: Decreased in situ expression of interleukin-10 receptor is correlated with the exacerbated inflammatory and cytotoxic responses observed in mucosal leishmaniasis. Infect. Immun. 73 (12), 7853-7859 (2005).
112. Peacock CS, Seeger K, Harris D et al.: Comparative genomic analysis of three Leishmania species that cause diverse human disease. Nat. Genet. 39(7), 839-847 (2007).
113. Smith DF, Peacock CS, Cruz AK: Comparative genomics: from genotype to disease phenotype in the leishmaniases. Int. J. Parasitol. 37(11), 1173-1186 (2007).